Abbott lowers 2026 sales growth forecast on medical device weakness
21/10/2026 12:30
Abbott lowers 2026 sales growth forecast on medical device weakness Oct 21 (Reuters) - Abbott Laboratories ABT.N lowered its annual sales growth forecast on Wednesday, after reporting softer-than-expected demand for its medical devices.
The company now expects 2026 sales growth of about 6%, compared with its prior expectation of between 6.5% and 7.5%.
The medtech giant reported quarterly adjusted profit per share of $1.42, which was in line with analysts' average estimate, according to data compiled by LSEG.
(Reporting by Padmanabhan Ananthan and Christy Santhosh in Bengaluru; Editing by Joyjeet Das)
Recent news on Abbott Laboratories
See all newsBrief: Abbott Announces Availability Of Panbio Covid-19/Flu A&B Self-Test In Canada
Perrigo to sell infant formula business to MeridianMade for up to $175 million
Brief: Abbott Initiates Pivotal Trial For Cephea™ Device, An Innovative Treatment For Mitral Heart Valve Disease
Corrected: German startup NVision shows new path to quantum computing chips in Nature paper
Brief: Abbott Receives FDA Approval For First Device To Treat Leaks After Heart Valve Replacement